Pulmonary fibrosis. Pathways are slowly coming into light

American Journal of Respiratory Cell and Molecular Biology

Volumn 22, Issue 5, 2000, Pages 520-523

  Cooper Jr , J Allen D ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0034029097     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.22.5.f185     Document Type: Review

References (32)

1. 1. Ryu, J. H., T. V. Colby, and T. E. Hartman. 1998. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin. Proc. 73:1085-1101.
2. 2. Yagoda, A., B. Mukherji, C. Young, E. Etcubanas, C. Lamonte, J. R. Smith, C. T. Tan, and I. H. Krakoff. 1972. Bleomycin: an antitumor antibiotic: clinical experience in 274 patients. Ann. Intern. Med. 77:861-865.
3. 3. Cooper, Jr., J. A. D. 1997. Drug-induced lung disease. Adv. Intern. Med. 42:231-268.
4. 4. Adamson, I. Y. R., and D. H. Bowden. 1974. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 77:185-190.
5. 5. Cooper, Jr., J. A. D., R. J. Zitnik, and R. A. Matthay. 1988. Mechanisms of drug-induced pulmonary disease. Ann. Rev. Med. 39:395-404.
6. 6. Kuhn, C., J. Boldt, T. E. King, E. Crouch, T. Vartio, and J. A. McDonald. 1989. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis. 140:1693-1703.
7. 7. Hoyt, D. G., and J. S. Lazo. 1988. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-β precede bleomycin-induced pulmonary fibrosis in mice. J. Pharmacol. Exp. Ther. 246:765-771.
8. 1 in developing bleomycin-induced pulmonary fibrosis in rats. J. Clin. Invest. 92:632-637.
9. 9. Giri, S. N., D. M. Hyde, and M. A. Hollinger. 1993. Effect of antibody to transforming growth factor β on bleomycin-induced accumulation of lung collagen in mice. Thorax 48:959-966.
10. 10. Wang, Q., Y. Wang, D. M. Hyde, P. J. Gotwals, V. E. Koteliansky, S. T. Ryan, and S. N. Giri. 1999. Reduction of bleomycin-induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 54:805-812.
11. 11. Khalil, N., R. N. O'Connor, H. W. Unruh, P. W. Warren, K. C. Falnders, A. Kemp, O. H. Bereznay, and A. H. Greenberg. 1991. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 5:155-162.
12. 12. Ziesche, R., E. Hofbauer, K. Wittmann, V. Petkov, and L.-H. Block. 1999. A preliminary study of long-term treatment with Interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341:1264-1269.
13. 13. Phan, S., M. Gharaee-Kermani, F. Wolber, and U. S. Ryan. 1991. Stimulation of rat endothelial cell transforming growth factor-β production by bleomycin. J. Clin. Invest. 87:148-154.
14. 14. Khalil, N., O. Bereznay, M. Sporn, and A. H. Greenberg. 1989. Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J. Exp. Med. 170:727-737.
15. 15. Postlethwaite, A. E., J. Keski-Oja, H. L. Moses, and A. H. Kang. 1987. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J. Exp. Med. 165:251-256.
16. 16. Hannigan, M., L. Zhan, Y. Ai, and C. K. Huang. 1998. The role of p38 MAP kinase in TGF-beta1-induced signal transduction in human neutrophils. Biochem. Biophys. Res. Comm. 246:55-58.
17. 17. White, D. A., M. G. Kris, and K. E. Stover. 1987. Bronchoalveolar lavage cell populations in bleomycin-induced pulmonary toxicity. Thorax 42:551-552.
18. 18. Reynolds, H. Y., J. D. Fulmer, J. A. Kazmierowski, W. C. Roberts, M. M. Frank, and R. G. Crystal. 1977. Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J. Clin. Invest. 59:165-175.
19. 19. Yanagisawa, K., H. Osada, A. Masuda, M. Kondo, T. Saito, Y. Yatabe, K. Takagi, T. Takahashi, and T. Takahashi. 1998. Induction of apoptosis by Smad3 expression in response to TGF-β in human normal lung epithelial cells. Oncogene 17:1743-1747.
20. 20. Kuwano, K., N. Hagimoto, M. Kawasaki, T. Yatomi, N. Nakamura, S. Nagata, T. Suda, R. Kunitake, T. Maeyama, H. Miyazaki, and N. Hara. 1999. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J. Clin. Invest. 104:13-19.
21. 21. Seino, K.-I., K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:4484-4488.
22. 22. Mishra, A., N. A. Doyle, and W. J. Martin II. 2000. Bleomycin-mediated pulmonary toxicity: evidence for a p53-mediated response. Am. J. Respir. Cell Mol. Biol. 22:543-549.
23. 23. Chapman, H. A. 1999. A Fas pathway to pulmonary fibrosis. J. Clin. Invest. 104:1-2.
24. 24. Tschopp, J., M. Irmler, and M. Thome. 1998. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 10:552-558.
25. 25. Muller, M., S. Strand, H. Hug, E.-M. Heinemann, H. Walczak, W. J. Hofmann, W. Stremmel, P. H. Krammer, and P. R. Galle. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:403-413.
26. 26. Bennett, M., K. Macdonald, S. W. Chan, J. P. Luzio, R. Simari, and P. Weissberg. 1998. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290-293.
27. 27. Hagimoto, N., K. Kuwano, H. Miyazaki, R. Kunitake, M. Fujita, M. Kawasaki, Y. Kaneko, and N. Hara. 1997. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am. J. Respir. Cell Mol. Biol. 17:272-278.
28. 28. Kuwano, K., R. Kunitake, M. Kawasaki, Y. Nomoto, N. Hagimoto, Y. Nakanishi, and N. Hara. 1996. p21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 154:477-483.
29. 29. Antoniades, H., T. Galanopoulos, J. Neville-Golden, C. Kitritsy, and S. Lynch. 1994. p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine. J. Clin. Invest. 93:2206-2214.
30. 30. Piguet, P. F., M. A. Collart, C. G. Grau, Y. Kapanci, and P. Vassalli. 1989. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 170:655-663.
31. 31. Olman, M. A., N. Mackman, C. L. Gladson, K. M. Moser, and D. J. Loskutoff. 1995. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J. Clin. Invest. 96:1621-1630.
32. 32. Eitzman, D. T., R. D. McCoy, X. Zheng, W. P. Fay, T. Shen, D. Ginsburg, and R. H. Simon. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97:232-237.